-
These Biotech Companies Are Attempting to Use Improved Antibody Technology in the Fight To Eradicate COVID-19
Monday, November 29, 2021 - 10:03am | 1030Read More...Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Antibodies form the backbone of our immune systems. Each of these highly specialized blood proteins are...
-
Are Pfizer, Moderna, J&J Booster Shots a Panacea? This Company Says Its Broad-Spectrum Drugs to Fight COVID-19 Would Help End the Pandemic
Tuesday, November 2, 2021 - 9:19am | 1174Read More...Photo by Steven Cornfield on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. The inventor of one of the technologies being used to fight COVID-19 has cast doubts on the efficacy...
-
NanoViricides Announces COVID-19 Clinical Drug Candidate NV-CoV-2 was Effective Against SARS-CoV-2, Further Demonstrating Its Broad-Spectrum Pan-Coronavirus Activity
Monday, October 11, 2021 - 8:25am | 1700Read More...The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Shelton, Connecticut -- (October 11, 2021) - NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the...
-
NanoViricides Leaps Forward in its Quest to Defeat COVID-19
Tuesday, October 5, 2021 - 8:31am | 921Read More...Photo by Louis Reed on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Since the coronavirus pandemic started, scientists have worked to develop a vaccine to inoculate the...
-
NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development
Tuesday, September 14, 2021 - 7:32am | 2296Read More...The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Shelton, Connecticut - September 14, 2019 -- NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a global leader in...
-
COVID-19 Variants: What the Future Could Look Like After the Pandemic
Wednesday, July 14, 2021 - 7:02pm | 870Read More...The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Photo by Martin Sanchez on Unsplash Since the coronavirus pandemic shut down the world, scientists have clamored to develop vaccines to...
-
NanoViricides Review: What you Need to Know About the Company
Tuesday, June 22, 2021 - 12:49pm | 674Read More...The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. With the coronavirus changing the world in 2020, it makes sense that there’s a spotlight on science to prevent viruses from growing...
-
Biotechs That Might Benefit From Ebola Research
Monday, August 11, 2014 - 3:29pm | 389Read More...A lot of news has been circulating in regards to stocks that could benefit from the recent Ebola virus outbreak. Although investors might want to proceed with caution when it comes to these news-driven biotech stocks, it never hurts to review the landscape for potential opportunities. Related...
-
4 Ebola Researching Biotech Companies For Your Portfolio
Thursday, August 7, 2014 - 9:15am | 896Read More...With the death toll from West Africa’s Ebola outbreak reaching close to 1,000, serious interest is being taken into researching compounds that could both prevent outbreak and help those infected. Until recently, Ebola was a pretty rare disease, Dr. Jim Wilson told Benzinga, and the...
